MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 1, 2015, Pages 31-44

  Wittig, Burghardt ^a   Schmidt, Manuel ^b   Scheithauer, Werner ^c   Schmoll, Hans Joachim ^d  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MOLOGEN AG   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Anti cancer immunomodulation; Colorectal cancer; DSLIM ; Innate immune response; MGN1703; Toll like receptor 9

Indexed keywords

AGATOLIMOD; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; FLUOROURACIL; GEMCITABINE; IMMUNOMODULATING AGENT; IMO 2055; M 362; MGN 1703; ODN 1826; ODN 2216; PACLITAXEL; PLACEBO; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; CPG-OLIGONUCLEOTIDE; DNA; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT; LEFITOLIMOD; OLIGODEOXYRIBONUCLEOTIDE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLON CARCINOMA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTHERMIA; IMMUNOMODULATION; INJECTION SITE PRURITUS; INNATE IMMUNITY; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG CARCINOMA; MELANOMA; METASTASIS; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SENSORY NEUROPATHY; SINGLE DRUG DOSE; SKIN MANIFESTATION; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; AGONISTS; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG SCREENING; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DNA; DRUG EVALUATION, PRECLINICAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

EID: 84926089064     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.12.002     Document Type: Review

References (79)

1. Disis M.L. Immune regulation of cancer. J Clin Oncol 2010, 28(29):4531-4538.
2. Liu Y., Zeng G. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother 2012, 35(May (4)):299-308.
3. Ostrand-Rosenberg S. Immune surveillance: a balance between pro- and anti-tumor immunity. Curr Opin Genet Dev 2008, 18(1):11-18.
4. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6(10):715-727.
5. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331(6024):1565-1570.
6. Kreso A., Dick A. Evolution of the stem cell model. Cell Stem Cell 2014, 14:275-291.
7. June C.H. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007, 117(6):1466-1476.
8. Humphries C. Honing that killer instinct. Nature 2013, 504:S13-S15.
9. Rosenberg S.A. Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat Rev Clin Oncol 2011, 8:577-585.
10. Vacchelli E., Eggermont A., Fridman W., Galon J., Tartour E., Zitvogel L. Trial watch: adoptive cell transfer for anticancer immunotherapy. OncoImmunology 2013, 2. e24238-1-e24238-11.
11. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422.
12. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J., Valone F. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089-3094.
13. McDermott D., Atkins M. PD-1 as a potential target in cancer therapy. Cancer Med 2013, 2:662-673.
14. O'Day S., Hamid O., Urba W. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007, 110:2614-2627.
15. Salama A., Hodi F. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2011, 17:4622-4628.
16. Hodi F., O'Day S., McDermott D., Weber R., Sosman J., Haanen J. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
17. Lotze M., Zeh H., Rubartelli A., Spavero L., Amoscato A., Washburn N., et al. The grateful dead: damage-associated molecule pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007, 220:60-81.
18. Vivier E., Ugolini S., Blaise D., Chabannon C., Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012, 12(4):239-252.
19. Srikrishna G., Freeze H. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009, 11:615-628.
20. Lu H., Ouyang W., Huang C. Inflammation: a key event in cancer development. Mol Cancer Res 2006, 4:221-233.
21. Escamilla-Tilch M., Filio-Rodriguez G., Garcia-Rocha R., Mancilla-Herrera I., Mitchison N., Ruiz-Pacheco J., et al. The interplay between pathogen-associated and danger-associated molecular patterns: an inflammatory code in cancer?. Immunol Cell Biol 2013, 91:601-610.
22. Piccinini A., Midwood K. DAMPening inflammation by modulating TLR signalling. Mediat Inflamm 2010, 10.1155/2010/672395.
23. Huang B., Zhao J., Unkeless J., Feng Z., Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008, 27:218-224.
24. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13(May (5)):552-559.
25. Thompson M.R., Kaminski J.J., Kurt-Jones E.A., Fitzgerald K.A. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011, 3(6):920-940.
26. Holtick U., Scheulen M.E., von Bergwelt-Baildon M.S., Weihrauch M.R. Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs 2011, 20(3):361-372.
27. Reynolds J.M., Dong C. Toll-like receptor regulation of effector T lymphocyte function. Trend Immunol 2013, 34(10):511-519.
28. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813):740-745.
29. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11(5):373-384.
30. Collins L., Hajizadeh S., Holme E., Jonsson I., Tarkowski A. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J Leukoc Biol 2004, 75:995-1000.
31. Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464(7285):104-107.
32. Oka T., Hikoso S., Yamaguchi O., Taneike M., Takeda T., Tamai T. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012, 485:251-255.
33. Yamada H., Gursel I., Takeshita F., Conover J., Ishii K.J., Gursel M., et al. Effect of suppressive DNA on CpG-induced immune activation. J Immunol 2002, 169(10):5590-5594.
34. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdörfer B., Giese T., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168(9):4531-4537.
35. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5(10):987-995.
36. Ahmad-Nejad P., Häcker H., Rutz M., Bauer S., Vabulas R.M., Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002, 32(7):1958-1968.
37. Latz E., Schoenemeyer A., Visintin A., Fitzgerald K.A., Monks B.G., Knetter C.F., et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004, 5(2):190-198.
38. Brinkmann M.M., Spooner E., Hoebe K., Beutler B., Ploegh H.L., Kim Y.-M. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol 2007, 177(2):265-275.
39. Kim Y.-M., Brinkmann M.M., Paquet M.-E., Ploegh H.L. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 2008, 452(7184):234-238.
40. Guiducci C., Coffman R.L., Barrat F.J. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med 2009, 265(1):43-57.
41. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327(5963):291-295.
42. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009, 1(6):949-964.
43. Milas L., Scott M. Antitumor activity of Corynebacterium parvum. Adv Cancer Res 1978, 26:257-306.
44. Tokunaga T., Yamamoto T., Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis 1999, 52(1):1-11.
45. Eiró N., González L., González L.O., Andicoechea A., Fernández-Díaz M., Altadill A., et al. Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer. J Clin Immunol 2012, 32(4):848-854.
46. Connolly D.J., O'Neill L.A.J. New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol 2012, 12(4):510-518.
47. Galluzi L., Vacchelli E., Eggermont A., Fridman W., Galon J., Sautes-Fridman C. Trial watch: experimental toll-like receptor agonists for cancer therapy. OncoImmunology 2012, 1:699-716.
48. Krieg A.M. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007, 117(5):1184-1194.
49. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5(6):471-484.
50. Liu Y., Luo X., Yang C., Yu S., Xu H. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice. Vaccine 2011, 29(34):5778-5784.
51. Kim Y., Girardi M., Duvic M., Kuzel T., Link B., Pinter-Brown L., et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010, 63:975-983.
52. Link B.K., Ballas Z., Weisdorf D., Wooldridge J., Bossler A., Shannon M. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 2006, 29:558-568.
53. Pashenkov M., Goess G., Wagner C., Hormann M., Jandl T., Moser A. Phase II trial of a Toll-like receptor 9 - activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006, 24:5716-5724.
54. Thompson J., Kuzel T., Drucker B., Urba W., Bukowski R. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenterphase I/II study. Clin Genitourin Cancer 2009, 7:E58-E65.
55. Zent C., Smith B., Ballas Z., Wooldridge J., Link B., Call T. A phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53:211-217.
56. Hirsh V., Paz-Ares L., Boyer M., Rosell R., Middleton G., Eberhardt W. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:2667-2674.
57. Manegold C., van Zandwijk N., Szczesna A., Zatloukal P., Au J., Blasinska-Morawiec M. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012, 23:72-77.
58. Malik S., Hwang J., Cotarla I., Sullivan T., Karr R., Marshall J. Initial phase 1 results of gemcitabine, carboplatin and IMO-2055, a toll like receptor 9 (TLR9) agonist, in patients (pts) with advanced solid tumors: P3-112. J Thorac Oncol 2007, 2:S726-S727.
59. Machiels J., Kaminsky M., Keller U., Brummendorf T., Goddemeier T., Forssmann U. Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2013, 31:1207-1216.
60. Idera Pharma Inc. Press release: Idera pharmaceuticals announces top-line results from a phase 2 clinical trial of IMO-2055 in treatment of patients with advanced head and neck cancer. [Internet] Available from: =. http://ir.iderapharma.com/phoenix.zhtml?c=208904%26p=irol-newsArticle%26ID=1690928%26highlight.
61. ®. Mol Ther-Nucl Acids 2014, 3:e170.
62. Schmidt M., Anton K., Nordhaus C., Junghans C., Wittig B., Worm M. Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape. Allergy 2006, 61:56-63.
63. Schmidt M., Hagner N., Marco A., König-Merediz S.A., Schroff M., Wittig B. Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703. Nucleic Acid Ther 2015, in press.
64. Schmoll H.J., Wittig B., Arnold D., Riera-Knorrenschild J., Nitsche D., Kroening H., et al. Maintenance treatment with the immunomodulator MGN1703, a toll-like receptor 9 (TLR9) agonist, in patients with advanced colorectal carcinoma and disease control after induction therapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol 2014, 140(9):1615-1624.
65. Steinman R.M., Mellman I.S., Muller W.A., Cohn Z.A. Endocytosis and the recycling of plasma membrane. J Cell Biol 1983, 96(1):1-27.
66. Colonna M., Trinchieri G., Liu Y.-J. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004, 5(12):1219-1226.
67. Zhang Z., Wang F.S. Plasmacytoid dendritic cells act as the most competent cell type in linking antiviral innate and adaptive immune responses. Cell Mol Immunol 2005, 2(6):411-417.
68. Biesen R., Demir C., Barkhudarova F., Grün J.R., Steinbrich-Zöllner M., Backhaus M., et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthr Rheum 2008, 58(4):1136-1145.
69. York M.R., Nagai T., Mangini A.J., Lemaire R., van Seventer J.M., Lafyatis R. A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthr Rheum 2007, 56(3):1010-1020.
70. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Ann Rev Immunol 2011, 29:235-271.
71. Kandimalla E.R., Bhagat L., Cong Y.P., Pandey R.K., Yu D., Zhao Q., et al. Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem Biophys Res Commun 2003, 306:948-953.
72. Rutz M., Metzger J., Gellert T., Luppa P., Lipford G.B., Wagner H., et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004, 34:2541-2550.
73. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10:187-192.
74. Schmidt M., Cristobal J., Sander A., Brzezicha B., König-Merediz S.A., Wittig B. dSLIM immunomodulators induce anti-tumor responses both in vitro and in vivo. Mol Ther 2006, 13(Suppl. 1):S164. [Abstract 426].
75. Schmidt M., Brzezicha B., Chen Y., König-Merediz S.A., Wittig B. dSLIM immunomodulators reduce tumor growth in various animal tumor models. Mol Ther 2008, 16(Suppl. 1):S1-S389. [Abstract 935].
76. Volz B., Schmidt M., Kapp K., Schroff M., Tschaika M., Wittig B. Preclinical efficacy data of MGN1601, a tumor vaccine comprising 4-fold gene-modified and irradiated allogeneic tumor cells in combination with a DNA-based immunomodulator for the treatment of metastatic renal carcinoma. J Clin Oncol 2010, 28(Suppl.). [Abstract e15067].
77. Wittig B., Märten A., Dorbic T., Weineck S., Min H., Niemitz S., et al. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther 2001, 12(3):267-278.
78. Weihrauch M.R., Ansén S., Jurkiewicz E., Geisen C., Xia Z., Anderson K.S., et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 2005, 11(16):5993-6001.
79. Weihrauch M.R., Richly H., von Bergwelt-Baildon M., Schmidt M., Hacker U., Shimabukuro-Vornhagen A., et al. Phase I clinical study of the TLR9-agonist MGN1703 in patients with metastatic solid tumors. Eur J Cancer 2014, 10.1016/j.ejca.2014.11.002.